• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiac Toxicity Associated with HCV Direct Antiviral Agents.

作者信息

Ucciferri Claudio, Occhionero Alessandro, Vecchiet Jacopo, Falasca Katia

机构信息

Clinic of Infectious Diseases - Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Italy.

Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy.

出版信息

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018069. doi: 10.4084/MJHID.2018.069. eCollection 2018.

DOI:10.4084/MJHID.2018.069
PMID:30416701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6223545/
Abstract
摘要

相似文献

1
Cardiac Toxicity Associated with HCV Direct Antiviral Agents.与丙型肝炎病毒直接抗病毒药物相关的心脏毒性
Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018069. doi: 10.4084/MJHID.2018.069. eCollection 2018.
2
Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents.先天性心脏病成人患者丙型肝炎病毒感染的患病率及直接抗病毒药物治疗情况
South Med J. 2018 Mar;111(3):137-141. doi: 10.14423/SMJ.0000000000000774.
3
Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.在直接作用抗病毒药物时代，基于他汀类药物（3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂）治疗丙型肝炎病毒（HCV）感染相关疾病
F1000Res. 2016 Feb 26;5:223. doi: 10.12688/f1000research.7970.3. eCollection 2016.
4
High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection.慢性丙型肝炎病毒感染患者心脏功能障碍发生率高，且对抗病毒治疗有反应。
Clin Res Cardiol. 2017 Jul;106(7):551-556. doi: 10.1007/s00392-017-1086-1. Epub 2017 Feb 24.
5
Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.丙型肝炎病毒核心区的氨基酸替换可预测在全口服直接作用抗病毒治疗方案消除 HCV RNA 后发生肝癌。
J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.
6
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.系统评价：直接作用抗病毒药物时代丙型肝炎病毒筛查的经济评价。
Aliment Pharmacol Ther. 2019 May;49(9):1126-1133. doi: 10.1111/apt.15201. Epub 2019 Mar 6.
7
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.使用两种不同的COBAS TaqMan HCV检测方法在直接抗病毒治疗期间对治疗中的丙型肝炎病毒RNA进行比较。
J Clin Virol. 2017 Apr;89:51-56. doi: 10.1016/j.jcv.2017.02.008. Epub 2017 Feb 24.
8
[Application of direct antiviral drugs in special patients with HCV infection].[直接抗病毒药物在特殊丙型肝炎病毒感染患者中的应用]
Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):316-320. doi: 10.3760/cma.j.issn.1007-3418.2018.04.017.
9
Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.直接作用抗病毒药物时代，影响注射吸毒人群对丙型肝炎抗病毒疗效认知的因素。
Int J Drug Policy. 2018 Feb;52:115-122. doi: 10.1016/j.drugpo.2017.12.014.
10
Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.直接作用抗病毒药物清除丙型肝炎病毒可改善严重肝纤维化患者的颈动脉粥样硬化。
J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

引用本文的文献

1
ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I.ABT-333（达沙布韦）通过抑制I增加犬左心室细胞的动作电位持续时间并引发早期后去极化。
Pharmaceuticals (Basel). 2023 Mar 25;16(4):488. doi: 10.3390/ph16040488.
2
Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast.在 budding yeast 中分析抗肝炎 C 直接作用药物的生理缺陷。
Microb Biotechnol. 2021 Sep;14(5):2199-2213. doi: 10.1111/1751-7915.13904. Epub 2021 Aug 11.
3
Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection.在使用直接作用抗病毒药物治疗丙型肝炎感染时，可能影响肝脏肿瘤发生率的宿主药物遗传学因素。
Heliyon. 2021 May 3;7(5):e06908. doi: 10.1016/j.heliyon.2021.e06908. eCollection 2021 May.
4
Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis.心脏损伤生物标志物与 COVID-19 患者的死亡风险：一项系统评价和荟萃分析
Cardiol Res Pract. 2021 Mar 18;2021:9363569. doi: 10.1155/2021/9363569. eCollection 2021.
5
Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator.GLP-26 作为一种有效的乙型肝炎病毒衣壳组装调节剂的疗效、潜在心脏毒性和猴子药代动力学研究。
Viruses. 2021 Jan 15;13(1):114. doi: 10.3390/v13010114.

本文引用的文献

1
Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection.慢性丙型肝炎病毒感染患者的血小板减少症
Mediterr J Hematol Infect Dis. 2017 Mar 1;9(1):e2017019. doi: 10.4084/MJHID.2017.019. eCollection 2017.
2
Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells.胺碘酮与丙型肝炎病毒核苷酸抑制剂在人诱导多能干细胞衍生的心肌细胞和过表达HEK-293 Cav1.2的细胞中的相互作用。
Toxicol Appl Pharmacol. 2016 Oct 1;308:66-76. doi: 10.1016/j.taap.2016.08.006. Epub 2016 Aug 9.
3
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.直接作用抗病毒药物治疗慢性丙型肝炎病毒感染合并肝硬化患者的安全性和有效性。
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1821-1830.e6. doi: 10.1016/j.cgh.2016.07.001. Epub 2016 Jul 9.
4
Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned.胺碘酮与基于索磷布韦的丙型肝炎病毒感染治疗之间的相互作用：潜在机制及经验教训。
Gastroenterology. 2015 Nov;149(6):1315-7. doi: 10.1053/j.gastro.2015.09.031. Epub 2015 Sep 28.
5
Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.在接受胺碘酮治疗的患者中，首次使用索非布韦和达卡他韦后出现极重度心动过缓：2 例包括再挑战。
Gastroenterology. 2015 Nov;149(6):1378-1380.e1. doi: 10.1053/j.gastro.2015.07.051. Epub 2015 Aug 4.
6
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.与丙型肝炎治疗用核苷酸聚合酶抑制剂相关的心脏功能障碍。
Hepatology. 2015 Aug;62(2):409-16. doi: 10.1002/hep.27488. Epub 2015 May 26.
7
Induction with ribavirin in a relapsing patient with chronic HCV hepatitis.利巴韦林诱导治疗慢性丙型肝炎复发患者。
Braz J Infect Dis. 2012 May-Jun;16(3):297-9.
8
Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.应用造血生长因子治疗 HCV 肝炎抗病毒治疗相关血液学副作用。
Mediterr J Hematol Infect Dis. 2010 Mar 31;2(1):e2010003. doi: 10.4084/MJHID.2010.003.
9
The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells.CYP3A4 在胺碘酮相关肝毒性中的作用。
Biochem Pharmacol. 2011 Feb 1;81(3):432-41. doi: 10.1016/j.bcp.2010.11.002. Epub 2010 Nov 9.